|
1
|
Cheng HL, Mostoslavsky R, Saito S, Manis
JP, Gu Y, Patel P, Bronson R, Appella E, Alt FW and Chua KF:
Developmental defects and p53 hyperacetylation in Sir2 homolog
(SIRT1)-deficient mice. Proc Natl Acad Sci USA. 100:10794–1099.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
McBurney MW, Yang X, Jardine K, Hixon M,
Boekelheide K, Webb JR, Lansdorp PM and Lemieux M: The mammalian
SIR2alpha protein has a role in embryogenesis and gametogenesis.
Mol Cell Biol. 23:38–54. 2003. View Article : Google Scholar :
|
|
3
|
Horio Y, Hayashi T, Kuno A and Kunimoto R:
Cellular and molecular effects of sirtuins in health and disease.
Clin Sci (Lond). 121:191–203. 2011. View Article : Google Scholar
|
|
4
|
Ferrara N, Rinaldi B, Corbi G, Conti V,
Stiuso P, Boccuti S, Rengo G, Rossi F and Filippelli A: Exercise
training promotes SIRT1 activity in aged rats. Rejuvenation Res.
11:139–150. 2008. View Article : Google Scholar
|
|
5
|
Howitz KT, Bitterman KJ, Cohen HY, Lamming
DW, Lavu S, Wood JG, Zipkin RE, Chung P, Kisielewski A, Zhang LL,
et al: Small molecule activators of sirtuins extend Saccharomyces
cerevisiae lifespan. Nature. 425:191–196. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Jackson MD, Schmidt MT, Oppenheimer NJ and
Denu JM: Mechanism of nicotinamide inhibition and
transglycosidation by Sir2 histone/protein deacetylases. J Biol
Chem. 278:50985–50998. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Sauve AA, Moir RD, Schramm VL and Willis
IM: Chemical activation of Sir2-dependent silencing by relief of
nicotinamide inhibition. Mol Cell. 17:595–601. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ohanna M, Bonet C, Bille K, Allegra M,
Davidson I, Bahadoran P, Lacour JP, Ballotti R and Bertolotto C:
SIRT1 promotes proliferation and inhibits the senescence-like
phenotype in human melanoma cells. Oncotarget. 5:2085–2095. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Mao B, Hu F, Cheng J, Wang P, Xu M, Yuan
F, Meng S, Wang Y, Yuan Z and Bi W: SIRT1 regulates YAP2-mediated
cell proliferation and chemoresistance in hepatocellular carcinoma.
Oncogene. 33:1468–1474. 2014. View Article : Google Scholar
|
|
10
|
Hori YS, Kuno A, Hosoda R, Tanno M, Miura
T, Shimamoto K and Horio Y: Resveratrol ameliorates muscular
pathology in the dystrophic mdx mouse, a model for duchenne
muscular dystrophy. J Pharmacol Exp Ther. 338:784–794. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Rathbone CR, Booth FW and Lees SJ: Sirt1
increases skeletal muscle precursor cell proliferation. Eur J Cell
Biol. 88:35–44. 2009. View Article : Google Scholar :
|
|
12
|
Tanno M, Sakamoto J, Miura T, Shimamoto K
and Horio Y: Nucleocytoplasmic shuttling of the NAD+-dependent
histone deacetylase SIRT1. J Biol Chem. 282:6823–6832. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ripoli M, Barbano R, Balsamo T, Piccoli C,
Brunetti V, Coco M, Mazzoccoli G, Vinciguerra M and Pazienza V:
Hypermethylated levels of E-cadherin promoter in Huh-7 cells
expressing the HCV core protein. Virus Res. 160:74–81. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Haigis MC and Sinclair DA: Mammalian
sirtuins: Biological insights and disease relevance. Annu Rev
Pathol. 5:253–295. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ota H, Tokunaga E, Chang K, Hikasa M,
Iijima K, Eto M, Kozaki K, Akishita M, Ouchi Y and Kaneki M: Sirt1
inhibitor, Sirtinol, induces senescence-like growth arrest with
attenuated Ras-MAPK signaling in human cancer cells. Oncogene.
25:176–185. 2006.
|
|
16
|
McPherron AC, Lawler AM and Lee SJ:
Regulation of skeletal muscle mass in mice by a new TGF-beta
superfamily member. Nature. 387:83–90. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Thomas M, Langley B, Berry C, Sharma M,
Kirk S, Bass J and Kambadur R: Myostatin, a negative regulator of
muscle growth, functions by inhibiting myoblast proliferation. J
Biol Chem. 275:40235–40243. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zhang C, Mcfarlane C, Lokireddy S, Bonala
S, Ge X, Masuda S, Gluckman PD, Sharma M and Kambadur R:
Myostatin-deficient mice exhibit reduced insulin resistance through
activating the AMP-activated protein kinase signalling pathway.
Diabetologia. 54:1491–1501. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Langley B, Thomas M, Bishop A, Sharma M,
Gilmour S and Kambadur R: Myostatin inhibits myoblast
differentiation by down-regulating MyoD expression. J Biol Chem.
277:49831–49840. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Spiller MP, Kambadur R, Jeanplong F,
Thomas M, Martyn JK, Bass JJ and Sharma M: The myostatin gene is a
downstream target gene of basic helix-loop-helix transcription
factor MyoD. Mol Cell Biol. 22:7066–7082. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ewen ME, Xing YG, Lawrence JB and
Livingston DM: Molecular cloning, chromosomal mapping and
expression of the cDNA for p107, a retinoblastoma gene
product-related protein. Cell. 66:1155–1164. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Hannon GJ, Demetrick D and Beach D:
Isolation of the Rb-related p130 through its interaction with CDK2
and cyclins. Genes Dev. 7:2378–2391. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Mayol X, Graña X, Baldi A, Sang N, Hu Q
and Giordano A: Cloning of a new member of the retinoblastoma gene
family (pRb2) which binds to the E1A transforming domain. Oncogene.
8:2561–2566. 1993.PubMed/NCBI
|
|
24
|
Assoian RK and Yung Y: A reciprocal
relationship between Rb and Skp2: Implications for restriction
point control, signal transduction to the cell cycle and cancer.
Cell Cycle. 7:24–27. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kabra N, Li Z, Chen L, Li B, Zhang X, Wang
C, Yeatman T, Coppola D and Chen J: SirT1 is an inhibitor of
proliferation and tumor formation in colon cancer. J Biol Chem.
284:18210–18217. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Pardo PS and Boriek AM: The physiological
roles of Sirt1 in skeletal muscle. Aging (Albany NY). 3:430–437.
2011. View Article : Google Scholar
|
|
27
|
Olas B and Wachowicz B: Resveratrol, a
phenolic antioxidant with effects on blood platelet functions.
Platelets. 16:251–260. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Banerjee S, Bueso-Ramos C and Aggarwal BB:
Suppression of 7,12-dimethylbenz (a)anthracene-induced mammary
carcinogenesis in rats by resveratrol: Role of nuclear
factor-kappaB, cyclooxygenase 2, and matrix metalloprotease 9.
Cancer Res. 62:4945–4954. 2002.PubMed/NCBI
|
|
29
|
Lee SJ: Regulation of muscle mass by
myostatin. Annu Rev Cell Dev Biol. 20:61–86. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Taylor WE, Bhasin S, Artaza J, Byhower F,
Azam M, Willard DH Jr, Kull FC Jr and Gonzalez-Cadavid N: Myostatin
inhibits cell proliferation and protein synthesis in C2C12 muscle
cells. Am J Physiol Endocrinol Metab. 280:E221–E228.
2001.PubMed/NCBI
|
|
31
|
Rios R, Carneiro I, Arce VM and Devesa J:
Myostatin regulates cell survival during C2C12 myogenesis. Biochem
Biophys Res Commun. 280:561–566. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Wong S and Weber JD: Deacetylation of the
retinoblastoma tumour suppressor protein by SIRT1. Biochem J.
407:451–460. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Joulia D, Bernardi H, Garandel V,
Rabenoelina F, Vernus B and Cabello G: Mechanisms involved in the
inhibition of myoblast proliferation and differentiation by
myostatin. Exp Cell Res. 286:263–275. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Rathbone CR, Lees SJ and Booth F: Sirt1
increases satellite cell cycle progression. FASEB. 212007.
|
